Veritas In Silico, Mitsubishi Gas Chemical File Joint Patent for Cancer Drug

MT Newswires Live08-04 10:16

Veritas In Silico (TYO:130A) and Mitsubishi Gas Chemical (TYO:4182) jointly filed a composition-of-matter patent for a novel antisense oligonucleotide (ASO) drug candidate targeting lncRNA H19, which is associated with certain types of cancers, according to a Tokyo bourse filing on Monday.

The first-in-class nucleic acid ASO drug candidate will take eight to 10 years to develop, the release said.

Veritas In Silico plans to seek regulatory approval via relatively small-scale clinical trials while exploring partnership opportunities, followed by label expansion and global commercialization after approval.

Shares of Mitsubishi Gas Chemical rose over 3%, while Veritas In Silico fell 0.5% recently.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656864065?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 10:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656864065","market":"sg","top_or_hot":-1,"title":"Veritas In Silico, Mitsubishi Gas Chemical File Joint Patent for Cancer Drug","media":"MT Newswires Live","content":"<html><body><p> Veritas In Silico (TYO:130A) and <a href=\"https://laohu8.com/S/MBGCF\">Mitsubishi Gas Chemical</a> (TYO:4182) jointly filed a composition-of-matter patent for a novel antisense oligonucleotide (ASO) drug candidate targeting lncRNA H19, which is associated with certain types of cancers, according to a Tokyo bourse filing on Monday.</p><p>The first-in-class nucleic acid ASO drug candidate will take eight to 10 years to develop, the release said.</p><p>Veritas In Silico plans to seek regulatory approval via relatively small-scale clinical trials while exploring partnership opportunities, followed by label expansion and global commercialization after approval.</p><p>Shares of Mitsubishi Gas Chemical rose over 3%, while Veritas In Silico fell 0.5% recently.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veritas In Silico, Mitsubishi Gas Chemical File Joint Patent for Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeritas In Silico, Mitsubishi Gas Chemical File Joint Patent for Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-04 10:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Veritas In Silico (TYO:130A) and <a href=\"https://laohu8.com/S/MBGCF\">Mitsubishi Gas Chemical</a> (TYO:4182) jointly filed a composition-of-matter patent for a novel antisense oligonucleotide (ASO) drug candidate targeting lncRNA H19, which is associated with certain types of cancers, according to a Tokyo bourse filing on Monday.</p><p>The first-in-class nucleic acid ASO drug candidate will take eight to 10 years to develop, the release said.</p><p>Veritas In Silico plans to seek regulatory approval via relatively small-scale clinical trials while exploring partnership opportunities, followed by label expansion and global commercialization after approval.</p><p>Shares of Mitsubishi Gas Chemical rose over 3%, while Veritas In Silico fell 0.5% recently.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4200","symbol_name":"专卖店","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2656864065","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656864065","pubTimestamp":1785809760,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Veritas In Silico  and Mitsubishi Gas Chemical  jointly filed a composition-of-matter patent for a novel antisense oligonucleotide  drug candidate targeting lncRNA H19, which is associated with certain types of cancers, according to a Tokyo bourse filing on Monday.The first-in-class nucleic acid ASO drug candidate will take eight to 10 years to develop, the release said.Veritas In Silico plans to seek regulatory approval via relatively small-scale clinical trials while exploring partnership opportunities, followed by label expansion and global commercialization after approval.Shares of Mitsubishi Gas Chemical rose over 3%, while Veritas In Silico fell 0.5% recently.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4200":"专卖店","BK4185":"保健护理机构","BK4561":"索罗斯持仓","ASO.AU":"ASTON MINERALS LTD","JYNT":"The Joint Corp.","ASO":"Academy Sports & Outdoors, Inc.","BK7095":"多种金属与采矿"},"translate_title":"Veritas In Silico 与三菱燃气化学申请抗癌药物联合专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASO":1,"ASO.AU":1,"JYNT":1.5},"content_text":"Veritas In Silico (TYO:130A) and Mitsubishi Gas Chemical (TYO:4182) jointly filed a composition-of-matter patent for a novel antisense oligonucleotide (ASO) drug candidate targeting lncRNA H19, which is associated with certain types of cancers, according to a Tokyo bourse filing on Monday.The first-in-class nucleic acid ASO drug candidate will take eight to 10 years to develop, the release said.Veritas In Silico plans to seek regulatory approval via relatively small-scale clinical trials while exploring partnership opportunities, followed by label expansion and global commercialization after approval.Shares of Mitsubishi Gas Chemical rose over 3%, while Veritas In Silico fell 0.5% recently.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656864065","isCrawlerRequest":true}